AI Article Synopsis

  • A study examined whether acetyl-L-carnitine (ALC) can improve symptoms of ADHD in children based on its prior successes in other conditions related to attention.
  • A multi-site, 16-week trial involved 112 children diagnosed with ADHD, who were randomly given either ALC or a placebo, with assessments made using standardized scales throughout the study.
  • While the overall results showed no significant benefits for the entire ADHD population, ALC showed potential effectiveness particularly in the inattentive type of ADHD, suggesting further research is warranted.

Article Abstract

Objective: To determine whether acetyl-L-carnitine (ALC), a metabolite necessary for energy metabolism and essential fatty acid anabolism, might help attention-deficit/hyperactivity disorder (ADHD). Trials in Down's syndrome, migraine, and Alzheimer's disease showed benefit for attention. A preliminary trial in ADHD using L-carnitine reported significant benefit.

Method: A multi-site 16-week pilot study randomized 112 children (83 boys, 29 girls) age 5-12 with systematically diagnosed ADHD to placebo or ALC in weight-based doses from 500 to 1500 mg b.i.d. The 2001 revisions of the Conners' parent and teacher scales (including DSM-IV ADHD symptoms) were administered at baseline, 8, 12, and 16 weeks. Analyses were ANOVA of change from baseline to 16 weeks with treatment, center, and treatment-by-center interaction as independent variables.

Results: The primary intent-to-treat analysis, of 9 DSM-IV teacher-rated inattentive symptoms, was not significant. However, secondary analyses were interesting. There was significant (p = 0.02) moderation by subtype: superiority of ALC over placebo in the inattentive type, with an opposite tendency in combined type. There was also a geographic effect (p = 0.047). Side effects were negligible; electrocardiograms, lab work, and physical exam unremarkable.

Conclusion: ALC appears safe, but with no effect on the overall ADHD population (especially combined type). It deserves further exploration for possible benefit specifically in the inattentive type.

Download full-text PDF

Source
http://dx.doi.org/10.1089/cap.2007.018DOI Listing

Publication Analysis

Top Keywords

acetyl-l-carnitine alc
8
attention-deficit/hyperactivity disorder
8
baseline weeks
8
inattentive type
8
combined type
8
adhd
5
alc attention-deficit/hyperactivity
4
disorder multi-site
4
multi-site placebo-controlled
4
placebo-controlled pilot
4

Similar Publications

Lipids in cumulus-oocyte complexes are important actors in molecular signalling pathways and are influenced by maturation conditions. Acetyl-L-carnitine (ALC) is a carrier involved in fatty acid transport and is a promoter of β-oxidation. Although the embryonic development potential of oocytes can be improved when ALC is added to the maturation medium, the effects of ALC on the lipid content and composition of oocytes and cumulus cells remain unknown.

View Article and Find Full Text PDF

COVID-19 is associated with neuropsychiatric symptoms, such as anosmia, anxiety, depression, stress-related reactions, and psychoses. The illness can cause persistent cognitive impairment and "brain fog", suggesting chronic brain involvement. Clinical entities of ongoing symptomatic COVID-19 and Post COVID Syndrome (PCS) mainly present neuropsychiatric symptoms such as dysgeusia, headache, fatigue, anxiety, depression, sleep disturbances, and post-traumatic stress disorder.

View Article and Find Full Text PDF

Oseltamivir phosphate (Tamiflu) alters neurobehavior of zebrafish larvae by inducing mitochondrial dysfunction.

Sci Total Environ

December 2024

Gansu Key Laboratory of Biomonitoring and Bioremediation for Environmental Pollution, School of Life Sciences, Lanzhou University, No. 222 South Tianshui Road, Lanzhou 730000, Gansu Province, China. Electronic address:

Antiviral drugs are widely used, yet their potential risks during early development, particularly within the central nervous system, remain contentious. Oseltamivir phosphate (OSE), a commonly prescribed antiviral, is increasingly detected in various environments. However, its toxicity to organisms and the underlying mechanisms are not well understood.

View Article and Find Full Text PDF

Background: Although nutraceutical-based treatments are often offered for erectile dysfunction (ED), their efficacy remains doubtful, and the choice of one substance over the other is challenged by the dearth of head-to-head comparative studies.

Aim: We aimed to compare the efficacy of available nutraceutical interventions, alone or in combination with phosphodiesterase type 5 inhibitors (PDE5i), in improving erectile function in men with ED through a network meta-analysis (NMA), which incorporates direct and indirect evidence into one model thus generating a hierarchy of effectiveness.

Methods: PubMed, Scopus, Web of Sciences, and Cochrane Library databases were searched for randomized placebo-controlled trials (RCTs) assessing the effect of any nutraceutical regimen in improving erectile function when compared to each other, placebo, and/or PDE5i in men with ED.

View Article and Find Full Text PDF

The debilitating, chronic symptoms of neuropathic pain result in decreased quality of life, depressed mood, and anxiety in patients suffering from neuropathic pain. Despite hundreds of dollars in monthly treatment-related costs, more than half of the patients report inadequate pain relief. Traditional first-line agents are expensive and may have disruptive side effects.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!